These final results, along with a former report displaying that a little-molecule ACKR3 agonist CCX771 reveals anxiolytic-like conduct in mice,2 support the thought of targeting ACKR3 as a novel strategy to modulate the opioid program, which could open new therapeutic avenues for opioid-associated disorders. Boost much healthier immune purpose: https://josefaq668vxv4.luwebs.com/profile